1. Scrip
  2. >>Digital Technologies
  3. >>AI

AI/ML Alliances May Give Larger Firms Another Edge, S&P Warns

 
• By Joseph Haas and Mary Jo Laffler

All big pharmas have proprietary artificial intelligence or machine learning platform or are partnering with third parties, according to a survey by S&P Global. Their deep pockets and early adoption are locking in a competitive advantage.

Jirsak/Shutterstock.com
Big pharma may be locking in an advantage in AI/ML applications (Shutterstock)

Alliances centered on artificial intelligence and machine learning (AI/ML) applications have become ubiquitous in the biopharmaceutical sector in recent years and are projected to accelerate. But a recent analysis by S&P Global warns that with their deep pockets for business development, big pharmas could establish enduring advantages over smaller competitors via significant investments in AI/ML.

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from AI

Menarini’s APAC CEO On Harnessing Digital Channels, RWE And BD Engine

 
• By Anju Ghangurde

In the final part of an interview with Scrip, Menarini’s Asia-Pacific CEO talks about the group’s digital capabilities, including their impact on a shortage issue in Australia, and leveraging RWE to inform healthcare practices across the region. The Italian company is also revving up its business development and alliance engine.

Sanofi Licenses Bispecific Candidates From AI-Driven Earendil

 
• By Joseph Haas

Deal Snapshot: Sanofi obtained global rights to a pair of bispecific antibody candidates for autoimmune and inflammatory bowel disorders from Helixon-affiliated AI firm Earendil.

Isomorphic Adds To Growing AI War Chest With First External Funding Round

 
• By Alaric DeArment

The four-year-old firm said it plans to advance programs toward the clinic from the funding round, which comes just over a year after signing two major pharma partnerships.

How Big Pharma Is Redefining, Scaling India GCCs Amid Tech Advances

 
• By Anju Ghangurde

Senior executives from AstraZeneca, BMS, Novo Nordisk, Takeda and Regeneron outline how big pharma's global capability centers (GCCs) in India are evolving beyond cost efficiency, focusing on innovation, “agile experimentation” and new technology including GenAI, virtual & augmented reality, with some positioned as COEs. Will Indian multinationals use the GCC approach?

More from Digital Technologies

Generative AI In Drug Discovery And India’s Potential To Leapfrog

 
• By Vibha Ravi

Heads of Novartis Biomedical, World Economic Forum and Indian majors like Sun Pharma’s SPARC, among others, discuss generative AI in drug discovery along with pointers for India to leapfrog the R&D process

With Fabhalta’s C3G Approval, Now Novartis Has To Find The Patients

 
• By Alaric DeArment

Novartis US president Victor Bultó talked to Scrip about the company’s efforts to reach patients with rare kidney diseases who are candidates for Fabhalta.

Amgen’s Research VP On Goldilocks Viscosity, AI’s Hinge Moment

 
• By Vibha Ravi

Amgen’s AI model to predict proteins in the “bright Goldilocks zone of viscosity” with over 80% accuracy minus a wet lab experiment holds immense potential, VP Research Haldar said at an event as he spoke about a “hinge moment” for AI in pharma